Advance your AML-targeted programs with 26 clinically relevant, systemically engrafted patient-derived models, designed to reflect disseminated disease and enable translationally meaningful readouts.
Enrollment open until May 1st
What Makes This Screen Unique
Systemic, Clinically Relevant AML Models
26 primary AML models engrafted systemically in severely immunodeficient mice, enabling assessment of leukemic burden across both peripheral blood and bone marrow.
This approach more closely reflects the disseminated nature of AML, supporting evaluation of therapeutic response in compartments that align with clinical disease. Models retain key patient-derived characteristics, including underlying biology and disease heterogeneity, providing a more translationally relevant foundation for efficacy studies.
Pretreated, Translationally Relevant Cohorts
Models derived from heavily pretreated patients, including prior exposure to:
-
Gilteritinib
-
Mylotarg
-
Experimental FLT3 inhibitors
-
Anti-CD33 ADCs
-
Stem cell transplant
Designed to better reflect real-world resistance and clinical complexity
Integrated Multi-Omic and Clinical Data
Each model is linked to deep molecular and clinical datasets, including:
-
Whole exome sequencing (WES)
-
RNA sequencing
-
Clinical annotations
-
Standard-of-care response data
Supporting biomarker discovery and translational decision-making.
Quantitative Disease Assessment
Terminal flow cytometry enables precise measurement of leukemic burden across peripheral blood and bone marrow, supporting robust efficacy evaluation.
Markers include: CD3, CD33, CD34, CD38, mCD45, hCD45, CD117, CD123, viability dye.
Optional Endpoint Analysis
Additional endpoint options available, including plasma-based Luminex assays, to further characterize treatment response. These analyses enable evaluation of circulating biomarkers and pharmacodynamic changes, providing additional context to efficacy readouts and supporting deeper interpretation of therapeutic activity.
Collaborative Benchmarking Arm (Shared SoC)
Participating clients gain access to shared standard-of-care benchmarking arms,
enabling:
- Cross-study comparability
- Standardized reference data across models
- Reduced duplication of control arms
- More efficient use of study budget
Collaborative Benchmarking Arm (Shared SoC)
Clients enrolling in the screen can access cost-shared reference arms to benchmark therapeutic responses while reducing investment.
-
5-Aza: CTG-2227, CTG-2235, CTG-2236, CTG-2239, CTG-2457, CTG-2700, CTG-2702, CTG-3438, 3440
-
Cytarabine: CTG-2240
-
Gilteritinib: CTG-2226, CTG-2232, CTG-2233, CTG-2237, CTG-2699, CTG-2704, CTG-3949, CTG-3950, CTG-4130, CTG-4196
-
Venetoclax: CTG-2228, CTG-2358, CTG-3931, CTG-4052, CTG-4053, CTG-4128
|
Model ID
|
SoC
|
|---|---|
|
CTG-2226
|
Gilteritinib
|
|
CTG-2227
|
Ziftomenib
|
|
CTG-2228
|
Ziftomenib
|
|
CTG-2232
|
Ziftomenib
|
|
CTG-2233
|
Gilteritinib
|
|
CTG-2235
|
5-Aza
|
|
CTG-2236
|
5-Aza
|
|
CTG-2237
|
Ziftomenib
|
|
CTG-2239
|
Ziftomenib
|
|
CTG-2240
|
Cytarabine
|
|
CTG-2358
|
Ziftomenib
|
|
CTG-2457
|
5-Aza
|
|
CTG-2699
|
Ziftomenib
|
|
CTG-2700
|
Ziftomenib
|
|
CTG-2702
|
5-Aza
|
|
CTG-2704
|
Ziftomenib
|
|
CTG-3438
|
5-Aza
|
|
CTG-3440
|
5-Aza
|
|
CTG-3931
|
Venetoclax
|
|
CTG-3949
|
Ziftomenib
|
|
CTG-3950
|
Ziftomenib
|
|
CTG-4052
|
Ziftomenib
|
|
CTG-4053
|
Venetoclax
|
|
CTG-4128
|
Venetoclax
|
|
CTG-4130
|
Ziftomenib
|
|
CTG-4196
|
Gilteritinib
|
-
Access a ready-to-run AML screening platform
-
Generate data in clinically relevant, systemic disease models
-
Benchmark your therapy against standard-of-care treatments
-
Leverage integrated multi-omic data for deeper insight
-
Reduce time, cost, and variability compared to standalone studies